Shots:
- The P-IIIb (APEX) trial assessed Tremfya (Q4W or Q8W) vs PBO for 24wks. in biologic-naïve PsA pts with inadequate response to SoCs, followed by a 24wk. active treatment period then a 12wk. safety follow-up; pts could enter a 2yr. extension phase prior to the final safety follow-up
- Trial showed reduced joint damage progression per PsA modified vdH-S score at Wk. 24, with mean change of 0.55 (Q4W) & 0.54 (Q8W) vs 1.35 from baseline; 67% (Q4W) & 63% (Q8W) had no radiographic progression vs 53%
- At Wk. 24, 67% (Q4W) & 68% (Q8W) achieved ACR20 vs 47%, while 41% (Q4W) & 42% (Q8W) pts reached ACR50 compared to 20%, with 73% (Q4W) & 68% (Q8W) vs 31% pts achieving IGA 0/1
Ref: PRNewswire | Image: Johnson & Johnson| Press Release
Related News:- Johnson & Johnson’s Tremfya Receives the EC’s Approval for Active Ulcerative Colitis (UC)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
